VLP Therapeutics to Develop Malaria Vaccine Under Army Grant; Wataru Akahata Comments

Health research managementVLP Therapeutics has received a $2.4 million grant from the U.S. Army to research and develop a vaccine against malaria.

The service branch awarded the research grant through the Defense Department’s Peer Reviewed Medical Research Program, the company said Thursday.

Wataru Akahata, founder and CEO of VLP Therapeutics, said the company has developed VLPM01, an experimental vaccine that works to home in on malaria parasite Plasmodium falciparum during its pre-erythrocytic stage.

Akahata added the firm has started preclinical trials of the vaccine candidate.

Gaithersburg, Maryland-based VLP Therapeutics is a biotechnology firm that aims to develop vaccines and antibody therapies for infectious diseases, cancer and other conditions through its inserted alphavirus virus-like particle technology platform, i-αVLP.

You may also be interested in...


Fluor to Compete for Tasks on GSA’s OASIS Contract; Tom D’Agostino Quoted

Fluor holds a five-year position to compete for task orders in multiple professional service areas under the General Services Administration's One Acquisition Solution for Integrated Services contract vehicle.

Damon Griggs CEO Dovel Technologies

Dovel Creates Advisory Board, Names New Leadership; Damon Griggs Quoted

Dovel Technologies has created an advisory board and appointed skilled leadership to provide guidance for the company’s strategic plan to drive innovation, customer success and employee growth. "I am thrilled these well-known leaders have chosen to join Dovel's Advisory Board," said Damon Griggs, Dovel CEO.

MC-130J Airlifter

Lockheed, USAF to Enter Airlifter Munition Delivery Project’s Fourth Phase

Lockheed Martin received a $25M contract to help the U.S. Air force assess the feasibility of deploying weapons through an airlifter under the fourth phase of USAF's Palletized Munitions Experimentation Campaign.